Id: | acc4650 |
Group: | 1sens |
Protein: | JNK2 |
Gene Symbol: | MAPK9 |
Protein Id: | P45984 |
Protein Name: | MK09_HUMAN |
PTM: | phosphorylation |
Site: | Thr183 |
Site Sequence: | RTACTNFMMTPYVVTRYYRAP |
Disease Category: | Immune system diseases |
Disease: | Atopic Dermatitis |
Disease Subtype: | |
Disease Cellline: | HaCaT? |
Disease Info: | |
Drug: | "7,3',4'-trihydroxyisoflavone" |
Drug Info: | "7,3',4'-trihydroxyisoflavone is a type of isoflavone with three hydroxyl groups at positions 7, 3', and 4'. It may have various biological activities. " |
Effect: | modulate |
Effect Info: | "The compound inhibits atopic inflammation, reduces IgE and inflammatory chemokines, partly by inhibiting the phosphorylation of ERK1/2 and JNK1/2 in the MAPK signaling pathway." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 31853913 |
Sentence Index: | 31853913_10 |
Sentence: | "7,3',4'-Trihydroxyisoflavone also reduced TNF-alpha/IFN-gamma-induced phosphorylation of ERK1/2 and JNK1/2. These results highlight several desirable properties of 7,3',4'-trihydroxyisoflavone, which support its use as a cosmeceutical ingredient for the treatment of atopic dermatitis." |
Sequence & Structure:
MSDSKCDSQFYSVQVADSTFTVLKRYQQLKPIGSGAQGIVCAAFDTVLGINVAVKKLSRPFQNQTHAKRAYRELVLLKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIHMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTACTNFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGELVKGCVIFQGTDHIDQWNKVIEQLGTPSAEFMKKLQPTVRNYVENRPKYPGIKFEELFPDWIFPSESERDKIKTSQARDLLSKMLVIDPDKRISVDEALRHPYITVWYDPAEAEAPPPQIYDAQLEEREHAIEEWKELIYKEVMDWEERSKNGVVKDQPSDAAVSSNATPSQSSSINDISSMSTEQTLASDTDSSLDASTGPLEGCR
Select PDB:
Target | Drug name | MOA | Phase | Status | Disease | Source |
---|---|---|---|---|---|---|
MAPK9 | BENTAMAPIMOD | c-Jun N-terminal kinase, JNK inhibitor | 2 | Completed | endometriosis | ClinicalTrials |
MAPK9 | TANZISERTIB | c-Jun N-terminal kinase 2 inhibitor | 2 | Terminated | idiopathic pulmonary fibrosis | ClinicalTrials |
MAPK9 | TANZISERTIB | c-Jun N-terminal kinase 2 inhibitor | 2 | Terminated | lupus erythematosus | ClinicalTrials |
MAPK9 | CC-401 | c-Jun N-terminal kinase 2 inhibitor | 1 | Terminated | myeloid leukemia | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACMAPK9-Thr183 | |
---|---|
Cancer | Intensity |
BRCA | |
COAD | |
HGSC | |
ccRCC | |
GBM | |
HNSC | |
LUAD | |
LUSC | |
non_ccRCC | |
PDAC | |
UCEC |
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.